文献速递耳科与耳神经小儿耳鼻咽喉

小鼠巨细胞病毒模型中延长与延迟更昔洛韦治疗后的听力

Hearing Following Prolonged and Delayed Ganciclovir Treatment in a Murine Cytomegalovirus Model.
PubMed 文献 · Laryngoscope · 2023-07-08

该研究在出生后第3天脑内接种小鼠巨细胞病毒或生理盐水的BALB/c小鼠中,比较标准、延迟和延长更昔洛韦(GCV)治疗窗口对听力的影响。延迟GCV改善ABR阈值但不改善DPOAE阈值;延长GCV未优于标准治疗;17日龄小鼠组织GCV浓度显著高于37日龄。

要点

  • 延迟GCV改善小鼠巨细胞病毒感染的ABR阈值,但不改善DPOAE阈值。
  • 延长GCV疗程未提供优于标准疗程的听力阈值。
  • 17日龄小鼠组织GCV浓度显著高于37日龄小鼠。

核心结论

  • 延迟GCV治疗较未治疗的小鼠巨细胞病毒感染小鼠在ABR上提供听力获益。
  • 延长GCV给药与较短疗程GCV治疗相比无获益。
  • GCV在全身和耳蜗中的药物浓度在较年长小鼠中低得多。

研究设计与样本

  • BALB/c小鼠在出生后第3天经脑内注射接种小鼠巨细胞病毒或生理盐水。
  • 腹腔注射GCV或生理盐水每12小时一次,分为标准治疗窗口(p3-p17)、延迟治疗窗口(p30-p44)或延长治疗窗口(p3-p31)。
  • 在4、6、8周龄时使用畸变产物耳声发射(DPOAE)和听性脑干反应(ABR)测试评估听阈。
  • 在p17和p37给予GCV后1小时采集小鼠血液和组织样本,通过液相色谱-质谱法评估浓度。

主要发现

  • 延迟GCV疗程改善小鼠巨细胞病毒感染小鼠的ABR阈值,但不改善DPOAE阈值。
  • 延长GCV疗程未提供优于标准治疗的听力阈值。
  • 所有17日龄小鼠组织的平均GCV浓度显著高于较年长的37日龄小鼠。

临床怎么用

  • 作者认为这些结果对儿童症状性先天性巨细胞病毒感染的临床管理具有潜在意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Compare hearing outcomes utilizing standard, prolonged and delayed ganciclovir (GCV) therapy in a murine model of cytomegalovirus (CMV). METHODS: BALB/c mice were inoculated with mouse cytomegalovirus (mCMV) or saline via intracerebral injection on postnatal day 3 (p3). Intraperitoneal GCV or saline was administered at 12 h intervals for the duration of the standard (p3-p17), delayed (p30-p44), or prolonged treatment windows (p3-p31). Auditory thresholds were assessed using distortion product otoacoustic emission (DPOAE) and auditory brainstem response (ABR) testing at 4, 6, and 8 weeks of age. Blood and tissue samples were harvested from mice on p17 and p37 one hour after GCV administration, and their concentrations were assessed via liquid chromatography-mass spectrometry. RESULTS: A delayed course of GCV improved ABR but not DPOAE thresholds in mCMV-infected mice. A prolonged course of GCV did not provide better hearing thresholds than those administered standard treatment. The average GCV concentration in all 17-day-old mice tissue was significantly higher than those in older 37-day-old mice. CONCLUSION: Delayed GCV treatment provided a hearing benefit on ABR over untreated mCMV infected mice. Prolonged CGV administration showed no benefit compared to a shorter duration GCV treatment. GCV drug concentrations both systemically and in the cochlea are much lower in older mice. These results have potential implications for the clinical management of cCMV infected children. LEVEL OF EVIDENCE: NA Laryngoscope, 134:433-438, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Hillam K, Suarez D, Nielson C, et al. Hearing Following Prolonged and Delayed Ganciclovir Treatment in a Murine Cytomegalovirus Model. Laryngoscope. 2023. PMID: 37421238. doi:10.1002/lary.30860

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。